Gujarat Themis Biosyn Limited
NSE: GUJTHEMPharmaceuticals
Share price
₹363.50
-1.21% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
56
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹4,725 Cr
P/E ratio
97.0
P/B ratio
13.7
ROCE
17.9%
ROE
17.4%
Dividend yield
0.2%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Our sales figures for this company step up at Mar 2012 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
Our sales figures for this company step up at Mar 2012 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Its earnings are falling, so growth cannot justify the price.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Gujarat Themis Biosyn Limited — this one | -7%/yr | 97.0× | — |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.1× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 79.4× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.2× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 100.5× | ₹25.1 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 46 of 130 on returns, 36 of 127 on growth, 3 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 17.9% on capital, ahead of 65% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the last five years it made ₹283 crore of cash from the business but spent ₹400 crore on plant and equipment, ₹117 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹1 crore to ₹162 crore.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 7 Aug 2026 · Consolidated · Unaudited
Revenue
₹44 Cr
Revenue vs last year
+21.6%
Revenue vs last quarter
-0.5%
Net profit
₹11 Cr
Profit vs last year
+23.0%
Profit vs last quarter
+0.6%
Net margin
25.3%
EPS
₹1.02
Earnings call transcript · 10 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹4,725 Cr
- Prev close
- ₹363.50
- 52w High
- ₹479
- 52w Low
- ₹225
- Enterprise value
- —
- Beta
- 1.9
- Price CAGR 1y
- -7.0%
- Price CAGR 3y
- 40.0%
- Price CAGR 5y
- 38.0%
- Price CAGR 10y
- 47.0%
Ratios
- Return on assets
- 9.3%
- PEG ratio
- -12.0
- P/E ratio
- 97.0
- P/B ratio
- 13.7
- EV / EBITDA
- —
- Industry P/E
- 37.6
- ROCE
- 17.9%
- ROCE 5y average
- 43.6%
- ROE
- 17.4%
- Debt / Equity
- 0.6
- Interest coverage
- 21.7
- Dividend yield
- 0.2%
- ROE 3y average
- 23.0%
- ROE last year
- 17.0%
Annual P&L
- Annual revenue
- ₹166 Cr
- Annual profit
- ₹47 Cr
- Operating margin
- 46.0%
- Net profit margin
- 28.3%
- EBITDA margin
- 45.8%
- Sales growth 3y
- 4.0%
- Sales growth 5y
- 13.0%
- Profit growth 3y
- -7.0%
- Profit growth 5y
- 9.0%
- EPS
- ₹4.3
- Sales growth TTM
- 10.0%
- Profit growth TTM
- -4.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹44 Cr
- Profit latest quarter
- ₹11 Cr
- YoY quarterly sales growth
- 22.1%
- YoY quarterly profit growth
- 22.2%
- OPM latest quarter
- 47.5%
Balance Sheet
- Book Value
- ₹22.2
- Face Value
- ₹1.0
- Total debt
- ₹162 Cr
- Total cash
- ₹6 Cr
- Borrowings
- ₹162 Cr
- Reserves / Equity
- 25.2
Cash Flow
- Operating cash flow
- ₹49 Cr
- Free cash flow
- -₹124 Cr
- FCF yield
- -2.7%
- Net cash flow
- -₹9 Cr
Shareholding
- Promoter holding
- 59.3%
- FII holding
- 4.9%
- DII holding
- 13.8%
- Public holding
- 21.9%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.8 | 4,27,322 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.4 | 2,54,531 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.4 | 1,79,389 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,15,012 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.4 | 1,10,915 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 30.0 | 1,07,221 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,261 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Guj. Themis Bio. | 379.50 | 101.4 | 4,939 | 0.18 | 11.1 | 22.2 | 43.8 | 22.1 | |
| Median | 417.90 | 34.5 | 2,208 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 28 | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 44 | 44 |
| Expenses | 22 | 25 | 23 | ||||||||||
| Material Cost | 7.73 | ||||||||||||
| Change in Inventories | -3.91 | ||||||||||||
| Purchases of Stock-in-Trade | 0 | ||||||||||||
| Employee Cost | 4.72 | ||||||||||||
| Other Expenses | 14 | ||||||||||||
| Operating Profit | 14 | 19 | 21 | ||||||||||
| OPM % | 43 | 52 | 47 | 42 | 46 | 50 | 48 | 44 | 48 | 43 | 39 | 44 | 48 |
| Other Income | 0 | 1 | 0 | ||||||||||
| Exceptional items (within Other Income) | 0 | ||||||||||||
| Interest | 0 | 2 | 2 | ||||||||||
| Depreciation | 2 | 4 | 4 | ||||||||||
| Profit before tax | 12 | 14 | 15 | ||||||||||
| Tax % | 25 | 24 | 27 | ||||||||||
| Net Profit | 9 | 11 | 11 | ||||||||||
| EPS in Rs | 0.83 | 1 | 1.02 | ||||||||||
| Diluted EPS in Rs | 1.02 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 170 | 151 | 166 |
| Expenses | 90 | ||
| Operating Profit | 76 | ||
| OPM % | 46 | ||
| Other Income | 2 | ||
| Interest | 0.36 | 3 | |
| Depreciation | 3.54 | 5.37 | 13 |
| Profit before tax | 79 | 66 | 62 |
| Tax % | 25 | ||
| Net Profit | 59 | 49 | 47 |
| EPS in Rs | 4.28 | ||
| Dividend Payout % | 0 |
Filed only on the standalone basis, so shown from it: Depreciation, Interest, Net Profit, Profit before tax, Sales.
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 18%
- 5 years
- 13%
- 3 years
- 4%
- TTM
- 10%
Compounded profit growth
- 10 years
- 26%
- 5 years
- 9%
- 3 years
- -7%
- TTM
- -4%
Stock price CAGR
- 10 years
- 47%
- 5 years
- 38%
- 3 years
- 40%
- 1 year
- -7%
Return on equity
- 10 years
- 32%
- 5 years
- 29%
- 3 years
- 23%
- Last year
- 17%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 | 11 |
| Reserves | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 237 | 277 |
| Borrowings | 6 | 3 | 4 | 1 | 6 | 8 | 5 | 1 | 0 | 3 | 30 | 162 |
| Other Liabilities | 9 | 8 | 9 | 8 | 8 | 14 | 14 | 18 | 17 | 17 | 22 | 54 |
| Total Liabilities | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
| Fixed Assets | 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 | 289 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 | 121 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 | 93 |
| Total Assets | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 39 | 64 | 91 | 49 |
| Cash from Investing Activity | -0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | -55 | -112 | -172 |
| Cash from Financing Activity | -3 | -3 | -0 | -4 | 5 | 2 | -5 | -14 | -13 | -9 | 26 | 115 |
| Net Cash Flow | -1 | -0 | 0 | 1 | 0 | -0 | 3 | -4 | 6 | 0 | 5 | -9 |
| Free Cash Flow | 2 | 3 | 0 | 5 | -5 | -3 | 7 | 26 | 16 | -10 | -25 | -124 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 24 | 71 | 26 | 52 | 87 | 59 | 80 | 44 | 58 | 76 | 134 |
| Inventory Days | 78 | 194 | 144 | 255 | 201 | 33 | 75 | 263 | ||||
| Days Payable | 947 | 240 | 84 | 145 | 131 | 99 | 218 | 625 | ||||
| Cash Conversion Cycle | 28 | 24 | 71 | -844 | 52 | 41 | 119 | 189 | 114 | -7 | -67 | -228 |
| Working Capital Days | -76 | -70 | -42 | -43 | -58 | 42 | 80 | 155 | 91 | 50 | 46 | 8 |
| ROCE % | 121 | 81 | 55 | 42 | 45 | 84 | 67 | 67 | 61 | 45 | 27 | 18 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Gujarat Themis Biosyn Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Fermentation media (dextrose / nutrients)
- Solvents
Sells to
- Lupin · anti-TB APIs (Rifampicin / Rifapentine) by fermentation
- Optimus Pharma · anti-TB APIs (Rifampicin) by fermentation
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE942C01045
Plants
- Vapi fermentation API facility
News impact
Big market events that reach Gujarat Themis Biosyn Limited, and how the effect spreads.
24 Sept, 23:47 IST · Market event · high impact
India-US trade deal ‘done and dusted’, execution awaits competitive advantage: Goyal
India and the US have finalised a trade deal, which should help Indian textiles, drug and software exporters win more US orders, while domestic-focused firms see little change.
Who it hits first
- Commerce Minister Piyush Goyal says the India-US trade deal is done and dusted, with only execution and final competitive-advantage details left.
- Lower US duties would directly cut costs for Indian exporters of clothes, bedsheets, generic drugs and software services.
- The five map seeds (Coal India, Oil India, GAIL, ABB India and Dabur) are domestic businesses with no US sales channel, so the deal barely touches them.
- Textiles exporters such as Welspun Living and Jindal Worldwide, which sell 41% and 90% of revenue abroad, stand first in line for new orders.
Who may gain
- US-facing textiles makers (bedsheets, garments, fabrics) through lower American tariffs.
- Generic-drug and drug-ingredient exporters through smoother US market access.
- Software and IT hardware firms through friendlier US tech ties and sentiment.
- Cotton, yarn and fabric suppliers at home as exporter order books refill.
- Domestic giants like Coal India, GAIL, Oil India, ABB India and Dabur see no direct gain.
Along the supply chain
Downstream
US retail chains, apparel brands, hospitals and technology buyers receive cheaper Indian goods and services, while Indian exporters expand shipping, warehousing and compliance work.
Upstream
Cotton growers, spinners, weavers and dyeing units, plus drug-ingredient and packaging suppliers, get second-order demand as exporters such as Welspun Living and Jindal Worldwide run fuller order books.
Where demand moves
Business
American retailers and importers place bigger clothing and home-textile orders as duties fall; US drug distributors pull more Indian generics; US firms keep outsourcing software and hardware work — business demand moves from US buyers to Indian exporters.
Capital
Investors rotate toward export-led textiles, pharma and IT shares on better earnings hopes, funding capacity additions; domestic defensives see no such inflow.
How it spreads across sectors
Capital Goods
Neutral — factory equipment demand follows domestic capex, not export duties.
Fast Moving Consumer Goods
Neutral — household brands live on Indian demand, not US trade.
Healthcare
Mildly positive — smoother US access helps drug exporters; hospitals and domestic diagnostics feel nothing.
Information Technology
Mildly positive on sentiment and services continuity; hardware makers gain if tech trade eases.
Oil, Gas & Consumable Fuels
Neutral — refiners and gas utilities sell at home and face no tariff channel.
Textiles
Positive first-order lift — lower US tariffs directly raise exporter volumes and margins.
When it plays out
Immediate
Export shares gap up on headlines; textiles names with confirmed US exposure lead while domestic seeds drift flat.
Medium term
Real order flows and margins decide — exporters with strong balance sheets convert the deal into earnings; pledged or leveraged names lag.
15 Sept, 05:00 IST · Market event · medium impact
New norms for faster drug rollout proposed; industry hails move
India plans to approve new medicines faster — good for drug makers like Sun Pharma that launch the most products.
Who it hits first
- Launch-heavy drug makers (Sun, Cipla) gain months of extra sales per approval.
- API suppliers and CDMOs see more client molecules to make.
- Hospitals unaffected — approvals do not fill beds.
Who may gain
- Sun Pharma most in absolute terms; quality API makers (Gujarat Themis) on volumes.
Along the supply chain
Downstream
Distributors and pharmacies stock more new products; hospitals mostly unaffected.
Upstream
API and intermediate makers gain volumes as more launches need ingredients.
Where demand moves
Business
Approval queues shorten; API/CDMO order books lengthen; patients access drugs sooner.
Capital
Money rotates into launch-heavy pharma and quality API names; avoids weak-balance-sheet theme traps.
How it spreads across sectors
Healthcare
Pharma and CDMO positive with a lag; hospitals neutral; weak names are value traps.
When it plays out
Immediate
Pharma stocks firm 1-3% on sentiment; weak names jump most (sell the jump).
Medium term
Actual approval acceleration over 1-3 years compounds launch-heavy winners.
Short term
Draft details and implementation dates decide how much is real vs hope.
15 Sept, 05:00 IST · Market event · high impact
Piramal Pharma Morpeth UK facility gets 7 FDA observations after Sep 3-11 inspection
A US drug watchdog found seven problems at Piramal Pharma UK factory — bad for its shares, while rival drug makers should barely feel it.
Who it hits first
- Piramal Pharma faces CDMO order pauses, deeper client audits and remediation costs at Morpeth.
- Seven observations exceed its own 4-observation precedents, signaling a tougher inspection outcome.
- Small pharma peers derate on sentiment as investors re-check Indian plant quality systems.
Who may gain
- Large quality leaders (Sun, Divi) may pick up marginal CDMO inquiries — too small to trade.
Along the supply chain
Downstream
US clients of Morpeth qualify backup suppliers slowly; no drug shortages indicated.
Upstream
No direct supply-chain link — this is a plant-quality event, not a supply disruption; API suppliers to Morpeth see minor order delays.
Where demand moves
Business
CDMO clients slow new Piramal orders and audit harder; no demand transfers at scale to peers.
Capital
Money trims small-pharma exposure on regulatory headlines; rotates to large quality pharma and hospitals-on-facts.
How it spreads across sectors
Healthcare
CDMO/API sentiment hit; hospitals untouched operationally; large pharma flat per precedent.
When it plays out
Immediate
Piramal stock down 2-5% on the headline; small peers dip 1-3% on sentiment.
Medium term
Clean re-inspection closes the episode; warning letter or import alert would extend damage to quarters.
Short term
Company corrective-action response and FDA classification (VAI vs OAI) decide whether this fades or escalates.
12 Sept, 04:23 IST · Market event · medium impact
Granules India promoter sells 1.72 crore shares worth Rs 1,500 crore; Goldman Sachs, BNP Paribas among buyers
Granules' owners sold Rs 1,500 crore of shares, which usually pushes the price down for a while — but big names like Goldman Sachs bought, which suggests the company itself is fine.
Who it hits first
- Granules faces 2-4% technical pressure from Rs 1,500 cr of new free float
- Quality buyers (Goldman, BNP) validate the business and likely mark a near-term floor
- Pharma peers see no fundamental change — ranked names are sentiment-only
Who may gain
- Goldman Sachs, BNP Paribas and other block buyers who accumulated at a discount
- Granules' public float and liquidity improve post-deal
Along the supply chain
Downstream
Formulation customers and distributors are unaffected; pricing and contracts continue as before.
Upstream
No supply-chain link — API suppliers and job-workers see no order change from a share sale.
Where demand moves
Business
No business demand shifts — this is a pure ownership transfer; Granules' API and formulations orders are untouched.
Capital
Promoter supply meets institutional demand at a small discount; some weak holders exit on the news while quality funds accumulate — net neutral to mildly positive for the register.
How it spreads across sectors
Healthcare
neutral — single-stock block with quality buyers; no sector read-through
When it plays out
Immediate
Granules dips 2-4% on supply overhang; peers flat
Medium term
Non-event for earnings — price rejoins fundamentals within a quarter
Short term
Block gets absorbed in 1-2 weeks; quality-holder register supports stability
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 23 Sep 2026 | unspecified | ₹0.67 |
|---|---|---|
| 4 Sep 2025 | unspecified | ₹0.67 |
Splits, bonuses & buybacks
- daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026
- bse-history fill: 2259 BSE bars before cutoff, code 506879, seam residual 1.00031× · 25 Feb 2025
- bse-history step 2/3: pre-listing action read from BSE's ruling (d1 0.000)0.6666666666666666× · 9 Aug 2024
- bse-history step 1/5: pre-listing action read from BSE's gap-open isin INE942C01029→INE942C01045@+0 (d1 0.027, vol x3.95)0.2× · 10 Oct 2023
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 23 Sep 2026 | L7 HITECH PRIVATE LIMITED | SELL | 6,53,056 | ₹410.72 |
| 23 Sep 2026 | L7 HITECH PRIVATE LIMITED | BUY | 100 | ₹413.37 |
| 24 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | BUY | 5,90,941 | ₹367.22 |
| 24 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | SELL | 5,90,941 | ₹367.48 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY2710 Aug 2026
- Annual report · 2024-2519 Aug 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.